| Literature DB >> 29514998 |
Devon K Taylor1, Nanette Mittereder2, Ellen Kuta2, Tracy Delaney2, Timothy Burwell2, Karma Dacosta3, Weiguang Zhao3, Lily I Cheng3, Charles Brown3, Anmarie Boutrin3, Xiang Guo4, Wendy I White4, Jie Zhu5, Huifang Dong5, Michael A Bowen5, Jia Lin5, Changshou Gao5, Li Yu6, Madhu Ramaswamy2, Marie-Claude Gaudreau2, Rob Woods5, Ronald Herbst2, Gianluca Carlesso1.
Abstract
Systemic sclerosis (SSc) is a debilitating inflammatory and fibrotic disease that affects the skin and internal organs. Although the pathophysiology of SSc remains poorly characterized, mononuclear cells, mainly macrophages and T cells, have been implicated in inflammation and fibrosis. Inducible costimulator (ICOS), which is expressed on a subset of memory T helper (TH) and T follicular helper (TFH) cells, has been shown to be increased in SSc and associated with disease pathology. However, the identity of the relevant ICOS+ T cells and their contribution to inflammation and fibrosis in SSc are still unknown. We show that CD4+ ICOS-expressing T cells with a TFH-like phenotype infiltrate the skin of patients with SSc and are correlated with dermal fibrosis and clinical disease status. ICOS+ TFH-like cells were found to be increased in the skin of graft-versus-host disease (GVHD)-SSc mice and contributed to dermal fibrosis via an interleukin-21- and matrix metalloproteinase 12-dependent mechanism. Administration of an anti-ICOS antibody to GVHD-SSc mice prevented the expansion of ICOS+ TFH-like cells and inhibited inflammation and dermal fibrosis. Interleukin-21 neutralization in GVHD-SSc mice blocked disease pathogenesis by reducing skin fibrosis. These results identify ICOS+ TFH-like profibrotic cells as key drivers of fibrosis in a GVHD-SSc model and suggest that inhibition of these cells could offer therapeutic benefit for SSc.Entities:
Mesh:
Substances:
Year: 2018 PMID: 29514998 DOI: 10.1126/scitranslmed.aaf5307
Source DB: PubMed Journal: Sci Transl Med ISSN: 1946-6234 Impact factor: 17.956